Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

275 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition.
Lara PN Jr, Quinn DI, Margolin K, Meyers FJ, Longmate J, Frankel P, Mack PC, Turrell C, Valk P, Rao J, Buckley P, Wun T, Gosselin R, Galvin I, Gumerlock PH, Lenz HJ, Doroshow JH, Gandara DR; California Cancer Consortium. Lara PN Jr, et al. Among authors: quinn di. Clin Cancer Res. 2003 Oct 15;9(13):4772-81. Clin Cancer Res. 2003. PMID: 14581348 Clinical Trial.
Angiogenesis-targeted therapies in prostate cancer.
Lara PN Jr, Twardowski P, Quinn DI. Lara PN Jr, et al. Among authors: quinn di. Clin Prostate Cancer. 2004 Dec;3(3):165-73. doi: 10.3816/cgc.2004.n.027. Clin Prostate Cancer. 2004. PMID: 15636683 Review.
Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy.
Levine AM, Tulpule A, Quinn DI, Gorospe G 3rd, Smith DL, Hornor L, Boswell WD, Espina BM, Groshen SG, Masood R, Gill PS. Levine AM, et al. Among authors: quinn di. J Clin Oncol. 2006 Apr 10;24(11):1712-9. doi: 10.1200/JCO.2005.03.4801. Epub 2006 Mar 6. J Clin Oncol. 2006. PMID: 16520466 Clinical Trial.
A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases.
Lara PN Jr, Stadler WM, Longmate J, Quinn DI, Wexler J, Van Loan M, Twardowski P, Gumerlock PH, Vogelzang NJ, Vokes EE, Lenz HJ, Doroshow JH, Gandara DR. Lara PN Jr, et al. Among authors: quinn di. Clin Cancer Res. 2006 Mar 1;12(5):1556-63. doi: 10.1158/1078-0432.CCR-05-2074. Clin Cancer Res. 2006. PMID: 16533781 Clinical Trial.
275 results